FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof of Concept for PPARγ Inverse Agonism in Advanced Urothelial Cancer By Ogkologos - March 23, 2026 6 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the FX-909-CLINPRO-1 study Source RELATED ARTICLESMORE FROM AUTHOR Pimicotinib Shows Robust Antitumour Activity and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumour FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous NSCLC Adding Gedatolisib to Fulvestrant, with or without Palbociclib, Improves PFS in Patients with HR-positive/HER2-negative, PIK3CA Wild-Type ABC MOST POPULAR Improving cancer care for the LGBTQ+ community July 26, 2021 Though the Pandemic Has Slowed, Many Are Still Struggling to Put... November 24, 2021 Neoadjuvant Nivolumab Plus Chemotherapy Improves OS Among Patients with Resectable NSCLC... June 24, 2025 ¿Puede el uso de un microondas causar cáncer? April 7, 2022 Load more HOT NEWS Coming together for Zynlonta Prognostic Significance of Lynch-like versus Sporadic MSI-H Endometrial Cancer Treated With... Young Mom-of-Three Learns She Has Stage 4 Breast Cancer, 5 Days... Melanoma Combination Studies with a Novel Anti-LAG3 Antibody Relatlimab
